1.3 The Initial Prenatal Laboratory Panel

Initial Routine Prenatal Laboratory Panel

Every pregnant patient should be offered a comprehensive laboratory assessment at the initial visit. The CNM must understand the rationale, normal ranges, and clinical interventions for each test.

Comprehensive Initial Panel Review

Initial Prenatal Panel
├── Hematology & Blood Bank
│   ├── ABO & Rh(D) Type (RhoGAM protocol if Rh-negative)
│   ├── Indirect Coombs (Antibody screen for irregular erythrocyte antibodies)
│   └── CBC with Differential (Hgb <11.0 g/dL = 1st/3rd trimester anemia; MCV <80 fL triggers electrophoresis)
├── Infectious Disease Screening
│   ├── Rubella IgG (MMR is live virus; non-immune get postpartum vaccine)
│   ├── Varicella IgG (Non-immune exposed get VZIG within 96h to 10 days)
│   ├── Syphilis: RPR/VDRL or Reverse Algorithm (Benzathine penicillin G is only curative therapy)
│   ├── Hepatitis B: HBsAg (If positive: infant needs HBIG + HepB vaccine within 12h; check HBV DNA)
│   └── HIV 4th Gen Ag/Ab Screen (Universal opt-out; viral load suppression prevents transmission)
└── Renal & Genitourinary
    ├── Urine Culture & Susceptibility (Screens for asymptomatic bacteriuria ≥10^5 CFU/mL)
    └── Cervical Cytology & STI NAAT (Chlamydia/Gonorrhea NAAT universal for age <25 or high risk)

Detailed Laboratory Rationale & Midwifery Interventions

1. ABO & Rh(D) Typing & Antibody Screen:

   • Rh-Negative Patients: Unsensitized Rh-negative women receive 300 mcg RhD immune globulin (RhoGAM) routinely at 28 weeks gestation and within 72 hours postpartum if the neonate is Rh-positive. RhIG is also indicated within 72 hours of any potential fetomaternal hemorrhage (miscarriage, ectopic, CVS, amniocentesis, abdominal trauma, external cephalic version, or antepartum bleeding).
   • Atypical Antibodies: Anti-D is the most common cause of hemolytic disease of the fetus and newborn (HDFN). However, anti-Kell (K) antibodies are particularly virulent; anti-Kell causes severe fetal anemia not merely through hemolysis, but by destroying erythroid progenitor cells in fetal liver. Any titer of anti-Kell requires maternal-fetal medicine (MFM) consultation and middle cerebral artery (MCA) Doppler surveillance.

2. Complete Blood Count (CBC):

   • Physiologic Anemia of Pregnancy: Plasma volume expands by 45–50%, whereas red cell mass expands by 20–30%, leading to physiologic hemodilution.
   • Diagnostic Cutoffs for Anemia:
     • First trimester: Hemoglobin <11.0 g/dL (Hematocrit <33%)
     • Second trimester: Hemoglobin <10.5 g/dL (Hematocrit <32%)
     • Third trimester: Hemoglobin <11.0 g/dL (Hematocrit <33%)
   • Microcytic Anemia (MCV <80 fL): Triggers serum ferritin to assess iron stores and hemoglobin electrophoresis to evaluate for beta-thalassemia minor, sickle cell trait, or other hemoglobinopathies.

3. Rubella and Varicella Immunity:

   • Assessed via quantitative or qualitative IgG titers.
   • Rubella Non-Immune: Congenital rubella syndrome causes cataracts, sensorineural deafness, and cardiac defects (PDA). The MMR vaccine is a live attenuated virus and is strictly contraindicated during pregnancy. The patient must be counseled to avoid known exposures and receive the MMR vaccine immediately postpartum prior to hospital discharge.
   • Varicella Non-Immune: If a non-immune pregnant woman has close contact with an individual with chickenpox or shingles, administer Varicella-Zoster Immune Globulin (VariZIG) within 96 hours (acceptable up to 10 days) to prevent severe maternal complications like varicella pneumonia.

4. Syphilis Serology:

   • Universal screening at initial visit; repeated in early third trimester (28 weeks) and at delivery for high-risk populations.
   • Algorithms: Traditional (nontreponemal RPR/VDRL confirmed by treponemal FTA-ABS or TP-PA) vs. Reverse sequence (automated treponemal immunoassay confirmed by quantitative RPR). Discrepant results require a secondary treponemal assay (TP-PA).
   • Treatment: Benzathine penicillin G (2.4 million units IM) is the only proven curative therapy that crosses the placenta to treat the fetus. Patients with a documented severe penicillin allergy must undergo formal penicillin desensitization followed by penicillin therapy; erythromycin, azithromycin, and doxycycline are unacceptable in pregnancy.
   • Jarisch-Herxheimer Reaction: Acute febrile reaction with uterine contractions and transient fetal heart rate decelerations within 24 hours of starting penicillin in early syphilis; patients require anticipatory guidance.

5. Hepatitis B Surface Antigen (HBsAg):

   • Positive HBsAg indicates acute or chronic maternal infection.
   • Neonatal Management: Within 12 hours of birth, the infant must receive both Hepatitis B Immune Globulin (HBIG) and the single-antigen Hepatitis B vaccine in separate anatomical limbs.
   • Maternal Management: Check maternal HBV DNA viral load in second trimester; if HBV DNA >200,000 IU/mL, initiate maternal antiviral therapy (tenofovir disoproxil fumarate) at 28–32 weeks to decrease perinatal transmission.

6. Urine Culture for Asymptomatic Bacteriuria (ASB):

   • Defined as isolation of ≥10^5 Colony-Forming Units (CFU)/mL of a single bacterial pathogen in a clean-catch midstream urine sample from an individual without urinary symptoms.
   • Pathophysiology: High progesterone levels induce smooth muscle relaxation, ureteral dilatation, and reduced bladder tone, while the enlarging dextrorotated uterus compresses the ureters at the pelvic brim. Untreated ASB progresses to acute pyelonephritis in up to 30–40% of affected pregnancies, carrying substantial risks of septic shock, acute respiratory distress syndrome (ARDS), and preterm labor.
   • Treatment: Prescribe a 5- to 7-day oral regimen based on susceptibility (e.g., nitrofurantoin, cephalexin, or amoxicillin-clavulanate). A test-of-cure urine culture is mandatory 1 to 2 weeks post-treatment.